Medcolcanna Organics Inc.
MCCNF
Other OTC0.06
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.25
3Y
- -
65.11
5Y
- -
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Felipe De La Vega
- Full Time Employees
- 90
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 400 – 5th Avenue SW Calgary AB Canada T2P 0L6
- IPO Date
- Aug 4, 2021
- Website
- medcolcanna.com
- Similar Companies
- Business
- Medcolcanna Organics Inc. (MCCNF) operates as a Canadian vertically integrated medical cannabis company with fully licensed cultivation, production, and distribution operations primarily based in Colombia, approximately 30 minutes from Bogotá, and extending to Switzerland. The company produces a range of high-quality organic cannabis-derived products, including extracts, distillates, isolates, and active pharmaceutical ingredients (API); pharmaceutical-grade products; dermocosmetics; food supplements; and veterinary products, which it supplies to nutraceutical, cosmetics, wellness, and medicinal markets globally, with a focus on exporting pharmaceutical-grade THC flower and derivatives to high-value regions such as Europe. Founded in 2010 and headquartered in Calgary, Alberta, Canada, Medcolcanna leverages state-of-the-art organic agricultural technology and pharmaceutical processes in optimal Colombian growing locations to serve international pharmaceutical partnerships and target conditions like epilepsy, chronic pain, chemotherapy-induced nausea, and central nervous system disorders through clinically trialed formulations developed in collaboration with the University of Groningen. In recent developments, the company reorganized operations over the past three years to enhance cost-effectiveness amid industry challenges, including workforce reductions, debt restructuring, closure of its extraction facility and compounding pharmacy laboratory, and a strategic pivot to become Latin America’s central hub for pharmaceutical-grade THC flower supply to Europe by boosting local production and processing flowers from countries like Costa Rica, Uruguay, and Canada; it also secured bridge loan arrangements with significant shareholders in 2023, achieved a successful arbitration outcome, and in February 2025 invited shareholders to an exclusive meeting to discuss revitalization and growth opportunities.